Consensus IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 16/06/2026 am IST			5-day change	1st Jan Change
570.00 ^USD	+1.63%		+1.57%	-15.75%

27/05	IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2026, May-27-2026 10:55 AM
26/05	IDEXX Laboratories Expands Fecal Antigen Testing Platform With Tapeworm Detection	MT

Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

ab737367cc69e7b0d860399dfc38749.nqJ-TI7kU1zTkUDBIq-SL0cjBitIV1ip2DBtyz76GIk.8PUmft2dZRaW3g7xRv_YGTF3a38nYx72qnc0jVqtYM_P-0oZ4LA-a6rfMw~2fde2d5daab73ab6fedaeb1e990663b3

Analysts' recommendations: IDEXX Laboratories, Inc.

06/05	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655	MT
06/05	Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785	MT
28/04	UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating	MT
27/04	Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating	MT
15/04	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
14/04	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
31/03	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
09/02	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
05/02	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
05/02	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
03/02	Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830	MT
03/02	UBS Adjusts IDEXX Laboratories PT to $730 From $750	MT
03/02	Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785	MT
03/02	BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830	MT
03/02	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700	MT
09/12	Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target	MT
10/11	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700	MT
04/11	UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating	MT
04/11	Jefferies Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating	MT
04/11	Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $805 From $765, Maintains Overweight Rating	MT
04/11	JPMorgan Adjusts Price Target on IDEXX Laboratories to $775 From $675, Maintains Overweight Rating	MT
04/11	BTIG Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating	MT
04/11	BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $823 From $761, Maintains Outperform Rating	MT
04/11	Rothschild & Co Redburn Adjusts PT on IDEXX Laboratories to $700 From $670, Maintains Neutral Rating	MT
04/11	Stifel Adjusts Price Target on IDEXX Laboratories to $775 From $700, Maintains Buy Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

570.00USD

Average target price

709.14USD

Spread / Average Target

+24.41%

High Price Target

805.00USD

Spread / Highest target

+41.23%

Low Price Target

470.00USD

Spread / Lowest Target

-17.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
Jefferies & Co.
UBS
Citigroup
Leerink Partners
Stifel Nicolaus
Piper Sandler
Barclays
BTIG
Morgan Stanley
JPMorgan Chase
BNP Paribas Exane
BofA Securities
Redburn Atlantic
Goldman Sachs
Atlantic Equities
Credit Suisse
Guggenheim
J.P. Morgan Chase